RhoVac AB strengthens project coordination and communication

RhoVac AB ("RhoVac") has hired Alexandra Ellervik to the Communication and Project Manager position. The recruitment means strengthening the organization, enabling the company to ensure continuation of high rate development and good communication with the market.

Over the years, RhoVac has initiated several collaborations with a number of universities and partners both nationally and internationally. The company is now strengthening its project management to ensure that good cooperation continues with high rates of development and optimal reporting of results. At the beginning of 2018, the clinical phase I/II study is expected to be completed and results from this study are expected to be reported in the second quarter of this year. In order to reach this, RhoVac needs to intensify communication with both company’s investors and its current and future partners.

Alexandra Ellervik brings many years of experience in project management in the private sector and in communication and education within healthcare industry. Alexandra Ellervik holds a MSc in molecular biology from Umeå University, Sweden, as well as a PhD in neurophysiology from Lund University, Sweden. Alexandra Ellervik took office on January 2, 2018.

Comments from RhoVac´s CEO, Anders Ljungqvist

-RhoVac is in a very active development phase and the recruitment of Alexandra allows us to maintain continued high pace in development. Alexandra has extensive experience as project manager, which is an important asset for our business. I am very pleased to welcome Alexandra to RhoVac.

For more information, please contact:

Anders Ljungqvist – VD, RhoVac AB

Phone: +45 4083 2365

E-mail: alj@rhovac.com

About RhoVac AB

RhoVac AB conducts research and development of immunotherapeutic drugs. The company's main focus is the development of a therapeutic cancer vaccine with the potential to prevent or limit metastasis in cancer. RhoVac's first drug candidate has completed pre-clinical phase and clinical phase I / II study has started spring 2017. RhoVac has its head office at Medicon Village in Lund, Sweden. The research has been conducted since 2007 primarily at the University Hospital in Herlev, Denmark, by a world-class research team in its niche. RhoVac is listed on AktieTorget, Sweden, a Multilateral Trading Facility (MTF), since March 2016. The share is traded under the ticker RHOVAC. Read more at www.rhovac.com

Subscribe

Documents & Links